Drug intelligence / Profile preview

naoluoshu ning granules

Development stage: Unknown
Lead developer: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Administration: Oral

Overview

Naoluoshu Ning granules is a Traditional Chinese Medicine (TCM) formulation developed by the Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences. It is currently being evaluated in Phase II clinical trials for the treatment of mild-to-moderate vascular dementia. The formulation is specifically designed to treat patients exhibiting the TCM pattern of yin deficiency with yang hyperactivity and blood stasis (阴虚阳亢、瘀血阻络证). As a botanical-based therapy, it aims to improve cognitive function and manage symptoms associated with cerebrovascular-related cognitive impairment through a multi-target approach characteristic of herbal medicine.

Other names: Naoluoshu Ning granules脑络疏宁颗粒

Beyond the preview

Go deeper on naoluoshu ning granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naoluoshu ning granules.

Explore the full profile